voriconazole. 1 Primary treatment with amphotericin B or quickly switching from azoles to amphotericin B seems to be mandatory for good clinical outcome. There is no evidence of a clear correlation between the MICs of amphotericin B and outcome of treatment, but high MICs should be taken into consideration for antifungal alternatives. 7 The combination of amphotericin B with caspofungin could have been beneficial in this case.
The patient described here was exposed to azoles previously, in contrast to the majority of azole-naive patients described in the Netherlands. 1 Resistance in antifungal-exposed patients may be expected as any antimicrobial treatment is associated with selective pressure and therefore with a risk of resistance emergence. 8, 9 A. fumigatus resistant to medical azoles has also been recovered from the environment. Molecular typing confirmed that environmental and clinical isolates harbouring cyp51A mutations were clustered, suggesting environmental transmission to azole-naive patients. This suggests that selection through a fungicide-based route may have taken place.
10 TR46/Y121F/ T289A-bearing strains have been found throughout the environment in the Netherlands and Belgium, but also recently in India. TR46/Y121F/T289A environmental strains in India were similar to the Dutch clinical strains.
11 All these cases may indicate the rapid and worrisome geographical spread of these new resistance mechanisms, possibly following the same path as TR34/ L98H, which now causes therapy-refractory infections worldwide.
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None to declare. Sir, Recently, there has been increased interest in testing unorthodox combinations of antimicrobials brought about by an alarming increase in antimicrobial resistance and a paucity of existing and new antimicrobials for the treatment of infections caused by multidrug-resistant organisms. 1 -4 One such example is the organisms colonizing the respiratory tracts and causing infective exacerbations in individuals with cystic fibrosis. We investigated a small sample of 17 multidrug-resistant Pseudomonas aeruginosa recovered from the respiratory secretions from such individuals by testing them against telavancin and daptomycin in combination with colistin. The Etest method used to assess the combinations and the calculation of the fractional inhibitory concentration index (FICI) have been described previously. 5 By CLSI breakpoint criteria, 14 (82.3%), 2 (11.8%) and 1 (5.9%) of the strains were susceptible, intermediate and resistant to colistin, respectively. 6 As expected, telavancin and daptomycin had no activity against the strains. An MIC 50 of 1 mg/L and MIC 90 of 4 mg/L were observed for colistin when tested alone and in combination with telavancin. In combination with daptomycin, the MIC 50 and MIC 90 of colistin increased to 3.0 and 8.0 mg/L, respectively. The results of the combination testing are presented in Table 1 . Hornsey et al.
1 also reported synergy with colistin + telavancin in combination when used against various Gramnegative organisms, but voiced concerns about the potential for this combination to cause nephrotoxicity. Using Galleria mellonella larvae infected with the multidrug-resistant AB210 strain of Acinetobacter baumannii, Hornsey et al.
2 demonstrated that telavancin and colistin in combination was significantly more active than either drug used alone.
As daptomycin does not appear to pose a risk for nephrotoxicity, it is unfortunate that we observed no synergy and a high rate of antagonism (41.2%) in the colistin + daptomycin combinations. 7 To our knowledge, this has not been reported by other workers. Kö rber-Irrgang et al. 3 reported no antagonism when testing the combination against 10 P. aeruginosa strains using Mueller-Hinton broth supplemented with 50 mg/L calcium. In time -kill studies that involved testing colistin + daptomycin against 15 clinical A. baumannii isolates, Malmberg et al. 4 reported an increase in the initial kill rate (1-4 h) in 13 of the 15 strains compared with colistin alone. They used Mueller -Hinton II broth and agar, which is cation adjusted to a standard calcium ion concentration of 25 mg/L (C. Malmberg, Antibiotic Research Unit, Uppsala University and Uppsala Academic Hospital, Uppsala, Sweden, personal communication).
We wonder if the antagonism we found with colistin + daptomycin is genuine or is perhaps an artefact of the method used to assess this combination. Daptomycin Etests incorporate a constant level of 50 mg/L calcium along the antimicrobial gradient, which is required for optimal activity of the daptomycin. 8 Calcium is known to have an inhibitory effect on polymyxins. 9 It is possible, therefore, that direct contact with the calcium from the daptomycin Etest is inhibiting the colistin. This would decrease the availability of colistin for antimicrobial action, resulting in elevation of the MIC, which is borne out by the MIC 50/90 of colistin when combined with daptomycin. Whether this explains the antagonism we observed or whether it is indeed genuine remains to be seen. Until this can be resolved, we would urge caution in the selection of methodology for testing colistin + daptomycin combinations.
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